This study suggests that the m6A-YTHDF1-EGFR axis promotes HCC progression following IRFA, and that targeted combined inhibition of m6A modification and EGFR represents a potential strategy for preventing HCC recurrence after RFA treatment. This evidence concerns the gene EGFR and hepatocellular carcinoma.